Policy briefing
Peptide compounding policy: an October reading guide
Read the peptide policy documents, compare the records, and prepare questions before evaluating a treatment offer.
An October 30, 2026 Federal Register notice announces a draft HHS enforcement-discretion policy for certain peptide substances used under section 503A while rulemaking continues. The notice is published; the policy remains nonbinding and establishes no enforceable rights. This is not permanent placement on the 503A bulks list or a new 503B policy. HHS says it may reconsider the approach if safety or product-quality concerns emerge. We treat the publication date as the date of the notice, without inferring a separate effective date.
Use this briefing to organize a closer reading of an offer. Start with the preparation index, work through the conditions, then compare the regulatory record with the company's announcement. Keep a space beside each point for the document you would need before treating a question as answered.
Preparation index
| Preparation | Routes and limits |
|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral, topical. |
| Epitalon acetate | Subcutaneous or intramuscular injections; intermittent courses. |
| KPV acetate | Topical or oral. |
| MOTS-c acetate | Subcutaneous or intramuscular injections. |
| Semax free base | Intranasal. |
| TB-500 acetate | Subcutaneous or intramuscular injections. |
Conditions to read together
- Appendix A membership.
- Appendix B identity: sequence, structure, molecular weight, formula; permitted route.
- Facility registered under section 510; valid certificate of analysis (COA) with Appendix B test results.
- Original manufacturer: section 510 FDA registration, CGMP, other FD&C requirements, physical location on COA. FDA-registered intermediaries document manufacturer/COA validation.
- Report products, all serious human adverse events regardless of causality, and quality issues to FDA and States where compounded and sent; events/issues through MedWatch. Include ingredient, strength/unit, original manufacturer/unique facility identifier, dosage form/administration route; patient labeling details event/quality reporting.
- Label: “This is a compounded drug product. Not for resale.”
- One Appendix A active ingredient only.
- Oral formulations: documented adequate human bioavailability for the specific formulation.
- Co-packaged or drug-containing delivery devices: FDA 510(k)-cleared syringes only.
- Remaining FD&C/503A requirements, including sanitation and valid patient-specific prescriptions.
Build a dated record
The notice concerns compounding by a state-licensed pharmacy, federal facility or licensed physician. It describes enforcement discretion during development of the bulks list, rather than FDA approval of the resulting drugs.
In your notes, give each document its own date and a short description of what you are trying to learn from it. Save the link beside that description. When you return to an older review, compare the dated update with the original passage instead of silently substituting one for the other. Mark any question you cannot resolve for a follow-up conversation.
Keep the two production roles separate
FDA explains that drugs compounded in accordance with section 503A's conditions are exempt from current good manufacturing practice (CGMP) requirements. Drugs made by 503B outsourcing facilities are subject to those requirements. FDA also says the law against insanitary conditions applies regardless of the compounding setting.
Give the ingredient manufacturer and the dispensing compounder separate lines in your notes. For each name, record the role you are asking about and the evidence you want explained. Then work back through condition four without swapping the two names. If an answer refers simply to “the facility,” ask the respondent to identify which organization and location they mean.
Read the company announcement as a plan
Hims & Hers' October 29 announcement previews Peptides+, with planned access to sermorelin, glutathione, B12, NAD+ and L-carnitine. It says BPC-157 and TB-500 would follow when allowable. It describes independent providers, licensed pharmacies and ongoing support. Its forward-looking disclosures address rollout uncertainty, limited clinical data and potentially unknown side effects. These are the company's plans and qualifications, not confirmation of current dispensing, a price, or a demonstrated benefit.
Before comparing an offer, write down what you actually received: an announcement, an invitation, a quote, or a proposed prescription. Ask for the next step in writing, including who will answer questions and which details still need confirmation. Keep your own record of the response and its date. If you cannot identify the product or the organization responsible for it, leave that part of your comparison unfinished.
Keep the treatment question in view
FDA's compounding FAQ distinguishes compounded medicines from approved generics. FDA does not verify compounded drugs' safety, effectiveness or quality before marketing. The agency says compounding can meet a need when an approved medicine is unsuitable, but poor preparation can cause contamination or incorrect ingredient strength. It advises investigating the pharmacy and discussing the individual situation with a healthcare professional.
Bring the specific decision you are facing to that conversation. Write it as a question rather than a conclusion: what information would help you decide whether to proceed, wait, or ask about another option? Request an explanation in words you can repeat back. Keep unanswered clinical questions separate from the administrative questions about an account, an appointment or a payment.
Reader questions
How can I keep my evidence notes useful?
Choose one statement from the offer and write down its exact wording. Beside it, list the document, section and date you would use to check it. Add a third column for what remains unanswered. Before sharing your notes, read them once as someone who has not seen the offer: can that person find the same passage and understand the question you still want resolved?
What could I ask the provider in writing?
Ask which preparation is being proposed, who would prescribe and dispense it, and what documentation they can explain before you decide. Request the full price and payment terms for the actual proposal, rather than filling those fields from an older offer. Include your practical questions about follow-up and whom to contact. Ask for clarification wherever the reply uses a term you do not understand.
What did this briefing verify?
We reviewed the linked policy, published notice, company announcement and FDA explanation. We did not inspect a supplier's certificate, laboratory work or manufacturing site, test a product, verify dispensing or prices, or conduct a new clinical evidence review. This briefing does not determine whether an individual prescription is appropriate.
Sources
- HHS policyHHSChecked
- October 30 noticeFederal RegisterChecked
- Peptides+ announcementHims & HersChecked
- Compounding questions and answersFDAChecked